UroGen Pharma Ltd. (NASDAQ:URGN) Receives Average Recommendation of “Buy” from Analysts

UroGen Pharma Ltd. (NASDAQ:URGNGet Free Report) has received a consensus rating of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $38.20.

A number of brokerages have commented on URGN. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Monday, March 10th. HC Wainwright cut their price target on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock.

View Our Latest Research Report on UroGen Pharma

Insider Buying and Selling

In other UroGen Pharma news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the company’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares in the company, valued at $1,622,719.24. This represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of URGN. KLP Kapitalforvaltning AS purchased a new position in UroGen Pharma during the 4th quarter worth approximately $59,000. Lazard Asset Management LLC purchased a new position in UroGen Pharma during the 4th quarter worth approximately $67,000. Aquatic Capital Management LLC purchased a new position in UroGen Pharma during the 4th quarter worth approximately $101,000. BNP Paribas Financial Markets grew its holdings in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma during the 4th quarter valued at $126,000. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Stock Performance

Shares of URGN stock opened at $11.07 on Friday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business has a 50 day moving average of $10.45 and a two-hundred day moving average of $11.65. UroGen Pharma has a 52 week low of $9.03 and a 52 week high of $20.70. The company has a market cap of $259.64 million, a P/E ratio of -3.51 and a beta of 1.12.

UroGen Pharma (NASDAQ:URGNGet Free Report) last issued its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. As a group, analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.

About UroGen Pharma

(Get Free Report

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

See Also

Analyst Recommendations for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.